Arcus Biosciences (NYSE:RCUS) General Counsel Sells $150,909.60 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) General Counsel Carolyn Tang sold 6,810 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total transaction of $150,909.60. Following the transaction, the general counsel directly owned 124,734 shares of the company’s stock, valued at $2,764,105.44. The trade was a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Arcus Biosciences Price Performance

NYSE RCUS traded down $0.26 on Thursday, reaching $22.02. The company’s stock had a trading volume of 1,175,874 shares, compared to its average volume of 1,200,446. The firm has a market cap of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75. The business has a 50-day moving average price of $20.82 and a 200 day moving average price of $13.98. Arcus Biosciences, Inc. has a 52 week low of $6.50 and a 52 week high of $26.40. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.22.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The firm had revenue of $26.00 million during the quarter, compared to analysts’ expectations of $19.89 million. During the same quarter last year, the company earned ($1.00) earnings per share. The company’s revenue for the quarter was down 45.8% compared to the same quarter last year. Sell-side analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Institutional Investors Weigh In On Arcus Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Amalgamated Bank increased its position in Arcus Biosciences by 3.9% in the 3rd quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock valued at $266,000 after acquiring an additional 736 shares in the last quarter. Creative Planning lifted its position in shares of Arcus Biosciences by 2.7% during the third quarter. Creative Planning now owns 29,629 shares of the company’s stock worth $403,000 after purchasing an additional 771 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Arcus Biosciences by 59.1% during the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after purchasing an additional 1,021 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Arcus Biosciences by 8.0% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company’s stock valued at $142,000 after purchasing an additional 1,294 shares in the last quarter. Finally, Parallel Advisors LLC increased its holdings in shares of Arcus Biosciences by 1.6% in the second quarter. Parallel Advisors LLC now owns 88,007 shares of the company’s stock valued at $716,000 after purchasing an additional 1,422 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Wall Street Zen upgraded Arcus Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. The Goldman Sachs Group lifted their price target on shares of Arcus Biosciences from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, October 30th. Bank of America upped their price objective on shares of Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research note on Friday, November 28th. Finally, Citigroup reaffirmed a “buy” rating on shares of Arcus Biosciences in a report on Friday, December 12th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Arcus Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $28.89.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.